Pyxis oncology stock prediction.

Pfizer-backed Pyxis hits 52-week high to cross $200M market cap. Pyxis Oncology ( NASDAQ: PYXS) shares reached a new 52-week high as the clinical-stage biotech backed by pharma giant Pfizer ( PFE ...Significantly high institutional ownership implies Pyxis Oncology's stock price is sensitive to their trading actions. A total of 5 investors have a majority stake in the company with 52% ownership.A. The latest price target for Pyxis Oncology ( NASDAQ: PYXS) was reported by RBC Capital on Tuesday, September 5, 2023. The analyst firm set a price target for 7.00 expecting PYXS to rise to ...On average, Wall Street analysts predict that Pyxis Oncology 's share price could reach $11.00 by Sep 5, 2024. The average Pyxis Oncology stock price prediction forecasts …

Get the latest Pyxis Oncology Inc (PYXS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.May 13, 2022 · As of May 13, 2022, the outstanding number of shares of Common Stock of Pyxis Oncology was 32,817,062. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a multi-asset multi-modality company ...

Dec 1, 2023 · PYXS Earnings Date and Information. Pyxis Oncology last announced its earnings results on November 7th, 2023. The reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.01. Pyxis Oncology has generated ($2.55) earnings per share over the last year ( ($2.55) diluted earnings per share).

Conference Call and Webcast Details. Pyxis Oncology management will host a conference call and live webcast on Tuesday, March 29, 2022, at 8:00 a.m. ET to discuss recent corporate updates. The ...[relinking] Home Overview Mission Vision Values An Overview of Pyxis Oncology, Inc. (PYXS)General Summary of Pyxis Oncology, Inc. Pyxis Oncology, Inc. (PYXS) is a biotechnology company that specializes in the development of innovative oncology therapies. Founded in 2018, the company has quickly made a name for itself in the …As of June 30, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 39,376,941. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage company focused on ...... shares outstanding. -$2.55. CAPs Rating. The percentage of Motley Fool CAPS user ratings that predict this company will outperform the market. Based on ...Their RAIN share price targets range from $11.00 to $24.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 1,431.5% from the stock's current price. View analysts price targets for RAIN or view top-rated stocks among Wall Street analysts.

As of August 15, 2022, the outstanding number of shares of Common Stock of Pyxis Oncology was 32,834,561. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is an oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. By leveraging our fully ...

Conference Call and Webcast Details. Pyxis Oncology management will host a conference call and live webcast on Tuesday, March 29, 2022, at 8:00 a.m. ET to discuss recent corporate updates. The ...

This results in Pyxis Oncology shareholders owning approximately 90 percent and Apexigen shareholders owning approximately 10 percent of the combined company’s common stock, assuming no exercise or settlement of the converted options, restricted stock units or warrants. Pyxis Oncology issued approximately 4.3 million shares of …About the Pyxis Oncology Inc stock forecast. As of 2023 November 24, Friday current price of PYXS stock is 1.400$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).As of May 10, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 38,245,287. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono and …Astellas Pharma Inc. -4.37%. ¥3.42T. PYXS | Complete Pyxis Oncology Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Milestone marks transition of Pyxis Oncology to a clinical-stage company Preliminary data anticipated in early 2024 CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc ...View the latest Pyxis Oncology Inc. (PYXS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

As of September 30, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 44,294,092. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage company focused on ...RBC Capital Markets has initiated coverage on Pyxis Oncology Inc (NASDAQ:PYXS) with an Outperform rating and a price target of...A. The latest price target for Pyxis Oncology ( NASDAQ: PYXS) was reported by RBC Capital on Tuesday, September 5, 2023. The analyst firm set a price target for 7.00 expecting PYXS to rise to ...Mar 31, 2023 · The stock options have a ten-year term and an exercise price of $4.01, the closing price of Pyxis Oncology’s common stock as reported by Nasdaq on March 31, 2023. Pyxis Oncology Stock Forecast, PYXS stock price prediction. Price target in 14 days: 1.719 USD. The best long-term & short-term Pyxis Oncology share price prognosis ...

As of August 15, 2022, the outstanding number of shares of Common Stock of Pyxis Oncology was 32,834,561. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is an oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. By leveraging our …Find the latest historical data for Pyxis Oncology, Inc. Common Stock (PYXS) at Nasdaq.com.

Asset Growth. -27.76%. Trailing 12-Months. The Pyxis Oncology stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and ...— Pyxis expands developmental capabilities with license to two ADC programs and ADC technology platform toolkit developed by Pfizer — CAMBRIDGE, Mass., March 18, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced that it has entered into a worldwide license agreement with Pfizer Inc. (NYSE:PFE) for the …Pyxis Oncology Inc. historical stock charts and prices, analyst ratings, financials, and today’s real-time PYXS stock price.[relinking] Home Overview Mission Vision Values An Overview of Pyxis Oncology, Inc. (PYXS)General Summary of Pyxis Oncology, Inc. Pyxis Oncology, Inc. (PYXS) is a biotechnology company that specializes in the development of innovative oncology therapies. Founded in 2018, the company has quickly made a name for itself in the …Pyxis Oncology issued approximately 4.3 million shares of common stock as a result of this transaction, and immediately post-acquisition, Pyxis Oncology is expected to have 43,872,248 shares of ...Nov 24, 2023 · Stock Price Forecast. According to 3 stock analysts, the average 12-month stock price forecast for Pyxis Oncology stock is $12, which predicts an increase of 674.19%. The lowest target is $7.00 and the highest is $15. On average, analysts rate Pyxis Oncology stock as a strong buy. Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, …As of August 15, 2022, the outstanding number of shares of Common Stock of Pyxis Oncology was 32,834,561. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is an oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. By leveraging our …BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers ...Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, …

Detailed statistics for Pyxis Oncology, Inc. (PYXS) stock, including valuation metrics, financial numbers, share information and more. Skip to main content. Log In Free Trial. ... The beta is 1.12, so Pyxis Oncology's price volatility has been higher than the market average. Beta (1Y) 1.12: 52-Week Price Change +0.66%: 50-Day Moving …

Oncology Pharma Inc () Stock Market info Recommendations: Buy or sell Oncology Pharma stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Oncology Pharma share forecasts, stock quote and buy / sell signals below.According to present data Oncology Pharma's ONPH shares and potentially its …

Pyxis Oncology issued approximately 4.3 million shares of common stock as a result of this transaction, and immediately post-acquisition, Pyxis Oncology is expected to have 43,872,248 shares of ...May 24, 2023 · Under the terms of the definitive merger agreement, Pyxis Oncology expects to issue approximately 4.4 million shares of its common stock to Apexigen stockholders to acquire Apexigen. For each share of Apexigen common stock, Pyxis Oncology will issue 0.1725 shares of its common stock, par value $0.001 per share. The Pyxis Oncology, Inc. stock price fell by -2.72% on the last day (Friday, 17th Nov 2023) from $1.47 to $1.43. It has now fallen 4 days in a row. During the last trading day the stock fluctuated 3.50% from a day low at $1.43 to a day high of $1.48. The price has fallen in 8 of the last 10 days and is down by -18.75% for this period.Mar 30, 2023 · Pfizer-backed Pyxis hits 52-week high to cross $200M market cap. Pyxis Oncology ( NASDAQ: PYXS) shares reached a new 52-week high as the clinical-stage biotech backed by pharma giant Pfizer ( PFE ... — Pyxis Oncology to host webcast with Key Opinion Leaders (KOLs) on April 27, 2021 at 1:00pm ET — CAMBRIDGE, Mass., April 27, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced the targets of its three antibody-drug conjugate (ADC) candidates along with additional details and preclinical data supporting the …Pyxis Oncology Stock Performance. NASDAQ PYXS opened at $1.63 on Monday. The firm has a 50-day moving average of $1.71 and a 200-day moving average of $2.29. The stock has a market cap of $72.24 ...The stock options have a ten-year term and an exercise price of $2.56, the closing price of Pyxis Oncology’s common stock as reported by Nasdaq on June 30, 2023. Pyxis Oncology is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Pyxis Oncology, Inc.On average, Wall Street analysts predict that Pyxis Oncology 's share price could reach $11.00 by Sep 5, 2024. The average Pyxis Oncology stock price prediction forecasts …Pyxis Oncology Inc (PYXS) stock is higher by 8.35% while the S&P 500 has fallen -0.1% as of 11:49 AM on Monday, Apr 3. PYXS is higher by $0.33 from the previous closing price of $4.01 on volume of 6,295,868 shares. Over the past year the S&P 500 is down -10.42% while PYXS is higher by 21.17%. PYXS lost -$3.65 per share the over the …Pyxis Oncology Stock Forecast, PYXS stock price prediction. Price target in 14 days: 1.719 USD. The best long-term & short-term Pyxis Oncology share price prognosis ...View the latest Pyxis Oncology Inc. (PYXS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

The Pyxis Oncology, Inc. stock price fell by -2.72% on the last day (Friday, 17th Nov 2023) from $1.47 to $1.43. It has now fallen 4 days in a row. During the last trading day the stock fluctuated 3.50% from a day low at $1.43 to a day high of $1.48. The price has fallen in 8 of the last 10 days and is down by -18.75% for this period.Stock prediction experts have been following Pyxis Oncology closely due to its growth potential. In recent months, BIOT's stock price has been fluctuating but overall, it shows an upward trend. According to some analysts' predictions, BIOT could double or even triple over the next few years if its drug candidates perform well during clinical ...Asset Growth. -27.76%. Trailing 12-Months. The Pyxis Oncology stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and ...Instagram:https://instagram. top 15 best gold brokers1000 bills for saletradovate'costar stock price APX801 is an NK cell engager designed to specifically activate natural killer cells leading to effective killing of tumor cells currently at the pre-clinical stage. APX801 was obtained as part of Pyxis Oncology’s acquisition of Apexigen in August 2023 and its development was previously paused by Apexigen. Pyxis, a multiplatform company, is ...Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs. First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate. Second dose level initiated in Phase 1 trial of PYX-201, an antibody-drug conjugate (ADC) candidate. Preliminary data from both trials on track for late-2023/early-2024 timeframe. high income investmentsbest self directed ira companies [relinking] Home History Owners Mission How It Works How It Makes Money A Brief History of Pyxis Oncology, Inc. (PYXS) Pyxis Oncology, Inc. (PYXS) is a biotechnology company focused on developing innovative cancer therapies. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts. 2020: Pyxis Oncology, Inc. was …Find the latest Pyxis Oncology, Inc. (PYXS) stock quote, history, news and other vital information to help you with your stock trading and investing. mlp list Mar 22, 2023 · As of December 31, 2022, Pyxis Oncology had cash and cash equivalents (including restricted cash) of $180.7 million, which is expected to fund operations into the first half of 2025. Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline ...